Article information
Full text is only aviable in PDF
References
[1.]
E. Gil-Néciga, A.L. Gobart.
Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos (estudio TRAIN).
Rev neurol, 46 (2008), pp. 461-464
[2.]
J. Sanchez Morillo, F.A. Demartini, L.A. Roca de Togores.
Interacción entre donepezilo y bloqueantes musculares en la enfermedad de Alzheimer.
Rev Esp Anestesiol Reanim, 50 (2003), pp. 97-100
[3.]
J. Baruah, J. Easby, G. Kesell.
Effects of acetylcholinesterase inhibitor therapy for Alzheimer's disease on neuromuscular block.
Br J Anaesth, 100 (2008), pp. 420
[4.]
E.P. Mc Coy, R.K. Mirakhur.
Comparison of the effects of neostigmine and edrophonium on the duration of action of suxamethonium.
Acta Anaesthesiol Scand, 39 (1995), pp. 744-747
[5.]
N.W. Fleming, S. Macres, J.F. Antognini, J. Vengco.
Neuromuscular blocking action of suxamethonium after antagonism of vecuronium by edrophonium, pyridostigmine or neostigmine.
Br J Anaesth, 77 (1996), pp. 492-495
[6.]
M.L. Heath.
Donepezil, Alzheimer's disease and suxamethonium.
Anaesthesia, 52 (1997), pp. 1018
[7.]
N.H. Greig, D.K. Lahiri, K. Sambamurti.
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Int Psychogeritr, 14 (2002), pp. 77-91
[8.]
C. Ibebunjo, F. Donati, G.S. Fox, D. Eshelby, J.I. Tchervenkov.
The effects of chronic tacrine therapy on d–tubocurarine blockade in the soleus and tibialis muscles of the rat.
Anesth Analg, 85 (1997), pp. 431436
Copyright © 2011. Sociedad Española de Neurología
